Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ALZN $1 next to explode a massive underpriced biotech with multiple phase 2 programs ongoing targeting blockbuster markets
NRXP $0.60 exploding higher about to release 2x Phase 3 results in the coming week
ALZN $0.95 -MC $6 m has HUGE product pipeline targeting blockuster indication like Alzheimer ,Depression ,Bipolar and so forth with some Phase 2 data readout expected later this year . the founder of the company is a large buyer of the stock see link below .
insider activity
http://openinsider.com/search?q=alzn
pipeline
https://alzamend.com/pipeline/
2x Phase 3 readouts expected in early Q2 while valuation is still super low at $44 million
NRXP hit $0.50 could run to $1+ ahead of the two phase 3 readouts in early Q2
NRXP $0.48 - 2x Phase 3 results from Bipolar Depression and Chronic back pain trials expected within weeks - very low valuation of only $44 million ...this has multi bagger potential
NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-announces-133000763.html
Company presentation
https://www.nrxpharma.com/wp-content/uploads/NRx-Corporate-Presentation.pdf
NRXP $0.48 - 2x Phase 3 results within weeks - very low valuation of only $44 million ...this has multi bagger potential
NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
https://finance.yahoo.com/news/nrx-pharmaceuticals-nasdaq-nrxp-announces-133000763.html
NRXP $0.41 - 2x Phase 3 results expected within 2 months , this one could run over 1 dollar in the coming weeks
NRXP $0.39 upp 2x Phase 3 readouts very soon
NRXP $0.30 -2x Phase 3 results expected within 2 months ..could run over $1 easily on positive results
check out their big pipeline
https://www.nrxpharma.com/pipeline/
NRXP $0.30 -2x Phase 3 results expected within 2 months ..could run over $1 easily on positive results
check out their big pipeline
https://www.nrxpharma.com/pipeline/
IGC $0.28 -Alzheimer Phase 2b data in Q2 ..Market cap only 18 million
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a "Buy" Recommendation and $3.00 Price Target
https://finance.yahoo.com/news/igc-pharma-announces-equity-analyst-170100061.html
IGC $0.28 -Alzheimer Phase 2b data in Q2 ..Market cap only 18 million
IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a "Buy" Recommendation and $3.00 Price Target
https://finance.yahoo.com/news/igc-pharma-announces-equity-analyst-170100061.html
NRXP $0.47- 2x Phase 3 results imminent while market cap is only $41 million
NRXP $0.47- 2x Phase 3 results imminent while market cap is only $41 million
NRXP $0.43 Phase 3 results imminent and NDA filing for another drug expected in Q2
NRXP $0.38 - Phase 2/3 results imminent should come by end of this month or ealry march .. market cap only $33 million
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Completion of Enrollment of its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
https://www.finanznachrichten.de/nachrichten-2024-01/61194548-nrx-pharmaceuticals-inc-nasdaq-nrxp-announces-completion-of-enrollment-of-its-phase-2b-3-trial-of-nrx-101-in-suicidal-treatment-resistant-bipolar-008.htm
Exceeded originally target enrollment (70) with n=74
Last patient, last visit expected in approximately six weeks; data to follow shortly thereafter
Positive data triggers milestone payment from Alvogen, as previously announced.
company presentation
https://www.nrxpharma.com/wp-content/uploads/NRx-Corporate-Presentation.pdf
NRXP $0.38 - Phase 2/3 results imminent should come by end of this month or ealry march .. market cap only $33 million
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Completion of Enrollment of its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
https://www.finanznachrichten.de/nachrichten-2024-01/61194548-nrx-pharmaceuticals-inc-nasdaq-nrxp-announces-completion-of-enrollment-of-its-phase-2b-3-trial-of-nrx-101-in-suicidal-treatment-resistant-bipolar-008.htm
Exceeded originally target enrollment (70) with n=74
Last patient, last visit expected in approximately six weeks; data to follow shortly thereafter
Positive data triggers milestone payment from Alvogen, as previously announced.
company presentation
https://www.nrxpharma.com/wp-content/uploads/NRx-Corporate-Presentation.pdf
UNCY $1 next bio bomb about to explode has an attractive kidney treatment near final data readout expected next quarter has low valution of $34 million and over 5 million shares acquired by institutional investors in last weeks .
“OLC’s novel characteristics have the potential to make it the best-in-class phosphate binder in the billion-dollar hyperphosphatemia market. Data from this pivotal trial is the last major component to complete our data package to file a New Drug Application (NDA) and will be informative for physicians as they consider a new potential therapy for their patients. We expect to report data from the trial in the second quarter of 2024 and file the NDA shortly thereafter.”
UNCY $1 next bio bomb about to explode has an attractive kidney treatment near final data readout expected next quarter has low valution of $34 million and over 5 million shares acquired by institutional investors in last weeks .
“OLC’s novel characteristics have the potential to make it the best-in-class phosphate binder in the billion-dollar hyperphosphatemia market. Data from this pivotal trial is the last major component to complete our data package to file a New Drug Application (NDA) and will be informative for physicians as they consider a new potential therapy for their patients. We expect to report data from the trial in the second quarter of 2024 and file the NDA shortly thereafter.”
UNCY $0.95 Blockbuster Phase 3 data in Q2 , has very low valuation of only 35 million .Over 5 million shares added by institutional investors in last weeks .
https://finance.yahoo.com/news/unicycive-therapeutics-issues-shareholder-letter-120300698.html
Topline Data from OLC Pivotal Trial Expected in Q2 2024 –– OLC will target the multibillion-dollar hyperphosphatemia market.
PTN $4 - Phase 3 results within days ,has low valuation of $65 million so it could double or even triple on positive results
Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
https://finance.yahoo.com/news/palatin-announces-database-lock-pl9643-123000682.html
Top-Line Results Expected in February
PTN $4 - Phase 3 results within days ,has low valuation of $65 million so it could double or even triple on positive results
Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
https://finance.yahoo.com/news/palatin-announces-database-lock-pl9643-123000682.html
Top-Line Results Expected in February
PTN $4 - Phase 3 results within days ,has low valuation of $65 million so it could double or even triple on positive results
Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
https://finance.yahoo.com/news/palatin-announces-database-lock-pl9643-123000682.html
Top-Line Results Expected in February
VNDA $3.65 -3x FDA Decisions in the coming weeks while trading MASSIVE below its $8.50 cash per share
see slide 6 for upcoming fda decision
https://www.vandapharma.com/pdfs/vanda_corporate_presentation_jan_24.pdf
FDA Decision for Insomnia treatment on March 4
FDA Decision for Bipolar treatment on April 2
FDA Decision for Gastroparesis treatment by mid September.
VNDA $3.65 -3x FDA Decisions in the coming weeks while trading MASSIVE below its $8.50 cash per share
see slide 6 for upcoming fda decision
https://www.vandapharma.com/pdfs/vanda_corporate_presentation_jan_24.pdf
FDA Decision for Insomnia treatment on March 4
FDA Decision for Bipolar treatment on April 2
FDA Decision for Gastroparesis treatment by mid September.
VNDA $3.65 -3x FDA Decisions in the coming weeks while trading MASSIVE below its $8.50 cash per share
see slide 6 for upcoming fda decision
https://www.vandapharma.com/pdfs/vanda_corporate_presentation_jan_24.pdf
FDA Decision for Insomnia treatment on March 4
FDA Decision for Bipolar treatment on April 2
FDA Decision for Gastroparesis treatment by mid September.
KZIA $0.35 -Phase 3 data imminent for cancer drug expected in early Q1 - market cap at laughable 9 million IF results are positive this low floater going to explode
A completed Phase II study in glioblastoma reported promising signals of clinical activity in 2021, and a pivotal study, GBM AGILE, is completed, with final data expected in first half of CY2024. Other clinical trials are ongoing in brain metastases, DMGs, and primary CNS lymphoma, with several of these having reported encouraging interim data.
KZIA $0.35 -Phase 3 data imminent for cancer drug expected in early Q1 - market cap at laughable 9 million IF results are positive this low floater going to explode
A completed Phase II study in glioblastoma reported promising signals of clinical activity in 2021, and a pivotal study, GBM AGILE, is completed, with final data expected in first half of CY2024. Other clinical trials are ongoing in brain metastases, DMGs, and primary CNS lymphoma, with several of these having reported encouraging interim data.
KZIA $0.35 -Phase 3 data imminent for cancer drug expected in early Q1 - market cap at laughable 9 million IF results are positive this low floater going to explode
A completed Phase II study in glioblastoma reported promising signals of clinical activity in 2021, and a pivotal study, GBM AGILE, is completed, with final data expected in first half of CY2024. Other clinical trials are ongoing in brain metastases, DMGs, and primary CNS lymphoma, with several of these having reported encouraging interim data.
EYEN $1.60 -FDA Decision on March 4 and has 3 more drugs in Phase 3 , market cap only 73 million
pipeline
https://eyenovia.com/pipeline/
EYEN $1.60 -FDA Decision on March 4 and has 3 more drugs in Phase 3 , market cap only 73 million
pipeline
https://eyenovia.com/pipeline/
PTN $2.95 -Phase 3 results in January - Market cap only $41 million
click link to see the upcoming milestones
https://finance.yahoo.com/news/palatin-provides-corporate-highlights-strategic-153300515.html
PTN $2.95 -Phase 3 results in January - Market cap only $41 million
click link to see the upcoming milestones
https://finance.yahoo.com/news/palatin-provides-corporate-highlights-strategic-153300515.html
IKT $1.50 Cancer drug near approval while market cap is at laughable 9 million trading below its cash of 17 million
We believe these data support the potential approval of IkT-001Pro and we intend to submit an NDA for up to 8 indications in adults with blood or stomach cancers, similar to the adult indications for imatinib mesylate. the U.S. Food and Drug Administration has granted a pre-New Drug Application (pre-NDA) meeting to be held in January 2024 to discuss the requirements for approval of IkT-001Pro
IKT $1.50 Cancer drug near approval while market cap is at laughable 9 million trading below its cash of 17 million
We believe these data support the potential approval of IkT-001Pro and we intend to submit an NDA for up to 8 indications in adults with blood or stomach cancers, similar to the adult indications for imatinib mesylate. the U.S. Food and Drug Administration has granted a pre-New Drug Application (pre-NDA) meeting to be held in January 2024 to discuss the requirements for approval of IkT-001Pro
IKT $1.38 - MC $8 m has Cancer treatment nearing NDA filing in the coming days we will know what is required for NDA submission .Cash balance is around $17 million or Cash untill end 2024 . Any good news from FDA expected in the coming days and this low floater will explode .
https://finance.yahoo.com/news/inhibikase-therapeutics-issues-letter-shareholders-133000568.html
" we will have a pre-NDA teleconference with the FDA in early 2024 to discuss the requirements of approval of IkT-001Pro for up to nine cancer indications. Recently, "
https://www.inhibikase.com/pipeline
IKT $1.38 - MC $8 m has Cancer treatment nearing NDA filing in the coming days we will know what is required for NDA submission .Cash balance is around $17 million or Cash untill end 2024 . Any good news from FDA expected in the coming days and this low floater will explode .
https://finance.yahoo.com/news/inhibikase-therapeutics-issues-letter-shareholders-133000568.html
" we will have a pre-NDA teleconference with the FDA in early 2024 to discuss the requirements of approval of IkT-001Pro for up to nine cancer indications. Recently, "
https://www.inhibikase.com/pipeline
MNOV $1.58 -3x Phase 3 Drugs and trading almost at cash level ..huge upside here
presentation
https://medicinova.com/wp-content/uploads/2023/11/Medicinova-Corporate_11-20-2023.pdf